Earlier this week, the FDA approved a new treatment option to help protect infants from RSV. It's called Nirsevimab and works as an antibody.
It now moves to the CDC panel, who is expected to approve it at its next meeting.
Joining Spectrum News 1 to talk more on this is pediatrician Dr. Joseph Sellers, the past president of the Medical Society of New York. He elaborates on this treatment, what that means and how this treatment would work, how important would this be to help treat children in the upcoming fall, and more.